IN BRIEF: 4basebio interim loss widens as research costs increase

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

4basebio PLC - Heidelberg, Germany-based life sciences company - Pretax loss in the six months to June 30 widens to £3.9 million from £2.7 million a year prior. Revenue grows 57% to £238,000 from £152,000. Research and non-captialised development expenses however increase 56% to £1.6 million from £1.0 million. Administrative expenses increase 23% to £1.6 million from £1.3 million, as sales and marketing expenses increase to £248,000 from £97,000. Looking ahead, expects to secure new clients in the second half of 2023.

Current stock price: 599.00 pence, closed 1.8% lower on Thursday in London

12-month change: up 4.2%

Copyright 2023 Alliance News Ltd. All Rights Reserved.